Comparing Ernexa Therapeutics (ERNA) and Its Rivals

Ernexa Therapeutics (NASDAQ:ERNA) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Ernexa Therapeutics to similar businesses based on the strength of its institutional ownership, analyst recommendations, profitability, risk, dividends, valuation and earnings.

Profitability

This table compares Ernexa Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-305.93%	-169.86%
Ernexa Therapeutics Competitors	-12,357.18%	-197.96%	-30.56%

Valuation & Earnings

This table compares Ernexa Therapeutics and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Ernexa Therapeutics	$580,000.00	-$14.08 million	-0.13
Ernexa Therapeutics Competitors	$734.01 million	$12.79 million	-15.19

Ernexa Therapeutics’ competitors have higher revenue and earnings than Ernexa Therapeutics. Ernexa Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 0.5% of Ernexa Therapeutics shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Ernexa Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1	1	1	0	2.00
Ernexa Therapeutics Competitors	9838	15122	45436	1587	2.54

Ernexa Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 1,503.42%. As a group, “Biotechnology” companies have a potential upside of 102.45%. Given Ernexa Therapeutics’ higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than its competitors.

Volatility and Risk

Ernexa Therapeutics has a beta of 2.75, indicating that its share price is 175% more volatile than the S&P 500. Comparatively, Ernexa Therapeutics’ competitors have a beta of 1.15, indicating that their average share price is 15% more volatile than the S&P 500.

Summary

Ernexa Therapeutics competitors beat Ernexa Therapeutics on 8 of the 13 factors compared.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.